Share This Article

Facebook LinkedIn
Twitter Reddit
Print Email
Pinterest Gmail
Yahoo
Money Morning
×
  • Invest
    • Best Stocks to Buy
    • Stock Forecasts
    • Stocks to Sell Now
    • Stock Market Predictions
    • Technology Stocks
    • Best REITs to Buy Now
    • IPO Stocks
    • Penny Stocks
    • Dividend Stocks
    • Cryptocurrencies
    • Cannabis Investing
    • Angel Investing
  • Trade
    • How to Trade Options
    • Best Trades to Make Now
    • Options Trading Strategies
    • Weekly Trade Recommendations
  • Retire
    • Income Investing Guide
    • Retirement Articles
  • More
    • Money Morning LIVE
    • Special Investing Reports
    • Our ELetters
    • Our Premium Services
    • Videos
    • Meet Our Experts
    • Profit Academy
Login My Member Benefits Archives Research Your Team About Us FAQ
  • Invest
    • Best Stocks to Buy
    • Stock Forecasts
    • Stocks to Sell Now
    • Stock Market Predictions
    • Technology Stocks
    • Best REITs to Buy Now
    • IPO Stocks
    • Penny Stocks
    • Dividend Stocks
    • Cryptocurrencies
    • Cannabis Investing
    • Angel Investing
    ×
  • Trade
    • How to Trade Options
    • Best Trades to Make Now
    • Options Trading Strategies
    • Weekly Trade Recommendations
    ×
  • Retire
    • Income Investing Guide
    • Retirement Articles
    ×
  • More
    • Money Morning LIVE
    • Special Investing Reports
    • Our ELetters
    • Our Premium Services
    • Videos
    • Meet Our Experts
    • Profit Academy
    ×
  • Subscribe
Enter stock ticker or keyword
×
5 Ways to Beat the Fed (and Crush Inflation)

Email this Article

Send with mail | ahoo instead.
Required Needs to be a valid email
Required Needs to be a valid email
3 Best Biotech Penny Stocks to Buy for March 2018
http://bit.ly/2HP5uJ8
Required Please enter the correct value.
Twitter
Stocks: JAGX, SGYP, VTGN, XON, ZIOP

3 Best Biotech Penny Stocks to Buy for March 2018

By Money Morning News Team, Money Morning • February 26, 2018

Start the conversation

Comment on This Story Click here to cancel reply.

Or to contact Money Morning Customer Service, click here.

Your email address will not be published. Required fields are marked *

Some HTML is OK

You wouldn't know it from following the mass media and Wall Street, but the stocks handing out the largest profits right now are in the biotechnology industry.

In fact, one of the three best biotech penny stocks to buy for March is a company developing treatments for the gut health of race horses, among other treatments.

Some analysts think it could skyrocket more than 792% over the next 12 months. That's enough to turn a $1,000 investment into $8,920 if these analysts are right.

However, investors must remember that penny stocks are risky investments.

Take VistaGen Therapeutics Inc. (Nasdaq: VTGN) for example. From Dec. 5 to Dec. 6, it climbed 188%, jumping from $0.92 to as high as $2.65.

But less than two weeks later, on Dec. 18, VTGN opened the trading day at $1.03. Investors who purchased the stock when it traded at $2.65 lost more than 61%.

That's why, at Money Morning, we advise our readers to never invest more than 2% of their overall portfolio in such risky investments and to never invest more money than you can afford to lose.

But for investors willing to accept the risks, biotech penny stocks pack major profit potential.

Silicon Valley Breakthrough: This tiny company's revolutionary new device is expected to "change the world on a scale hardly seen in human history." It could hand early investors a $78,000 windfall in the process. Here's how to get in...

And to help you find biotech penny stocks with potential, we're showing you three stocks with triple-digit potential according to the analysts who cover them.

All it takes is the announcement of positive clinical trial results to send this next stock soaring...

The Best Biotech Penny Stocks to Watch, No. 3: Synergy Pharmaceuticals Inc.

Synergy Pharmaceuticals Inc. (Nasdaq: SGYP) is a New York-based company developing therapies for gastrointestinal (GI) diseases. GI disorders can affect the stomach, small and large intestines, esophagus, and rectum.

SGYP's main product is plecanatide. It retails under the drug name Trulance.

Trulance/plecanatide is a tablet intended for once-daily use. It treats people with two conditions: chronic idiopathic constipation (CIC), and constipation-predominant irritable bowel syndrome (IBS-C).

In March of last year, Bezinga.com indicated that the full-year 2017 sales for Trulance were expected to top $53 million. For this year, sales are forecast to soar an astounding 575%. That would put total 2018 sales at $362 million.

This forecast puts the company in a good place for profitability. Wall Street analysts are responding accordingly.

Analysts at Canaccord Genuity, for example, placed a 12-year target price of $13 on the stock. From today's opening price of $1.95, that's a whopping 566% climb.

But Synergy Pharmaceuticals isn't the only potential triple-digit gainer on our list...

The Best Biotech Penny Stocks to Watch, No. 2: ZIOPHARM Oncology Inc.

Boston-based ZIOPHARM Oncology Inc. (Nasdaq: ZIOP) develops therapies to fight cancer.

ZIOP is currently partnered with another biotech, Intrexon Corp. (NYSE: XON), and Texas's world-renowned M.D. Anderson Cancer Center to create innovative immune-oncology treatments.

This program is aimed to help get the body's immune system to combat cancer, along with radiation treatment.

In mid-January, ZIOPHARM Oncology said it had begun phase 1 clinical trials to evaluate the combination of three drugs intended to fight malignant tumors affecting the spine and brain.

And it seems we're not the only ones keeping an eye on ZIOPHARM. Wall Street is very bullish on the stock, owing largely to its innovative therapies.

Griffin Securities, for example, set a one-year target price on the stock of $23. The shares currently trade at $3.77, so the achievement of that price target would return slightly over 510% to investors.

That's enough to turn a $1,000 investment into $6,100 a year from now.

But the company with the most impressive potential could skyrocket more than 792% over the next year...

Join the conversation. Click here to jump to comments…

Login
guest
guest
0 Comments
Inline Feedbacks
View all comments
LIVE
Visit Money Morning Live


Latest News

January 19, 2023 • By Money Morning Stock Research Team

These Stocks Could Go To $0

January 9, 2023 • By Money Morning Stock Research Team

The Government Is Pouring $391 Billion Into These Stocks - Buy Now

December 27, 2022 • By Money Morning Staff Reports

6 IPOs in 2023 You Can’t Afford to Miss
Trending Stories
ABOUT MONEY MORNING

Money Morning gives you access to a team of market experts with more than 250 years of combined investing experience – for free. Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors.

QUICK LINKS
About Us COVID-19 Announcements How Money Morning Works FAQs Contact Us Search Article Archive Forgot Username/Password Archives Profit Academy Research Your Team Videos Text Messaging Terms of Use
FREE NEWSLETTERS
Total Wealth Research Power Profit Trades Profit Takeover This Is VWAP Penny Hawk Trading Today Midday Momentum Pump Up the Close
PREMIUM SERVICES
Money Map Press Home Money Map Report Fast Fortune Club Weekly Cash Clock Night Trader Microcurrency Trader Hyperdrive Portfolio Rocket Wealth Initiative Extreme Profit Hunters Profit Revolution Warlock's World Quantum Data Profits Live Trading Alliance Trade The Close Inside Money Trader Expiration Trader Vega Burst Trader Flashpoint Trader Darknet Hyper Momentum Trader Alpha Accelerators

© 2023 Money Morning All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning.

Address: 1125 N Charles St. | Baltimore, MD, 21201 | USA | Phone: 888.384.8339 | Disclaimer | Sitemap | Privacy Policy | Whitelist Us | Do Not Sell or Share My Personal Information

wpDiscuz